Bleomycin-induced chromosomal aberrations in Down's syndrome lymphocytes.
Blood samples from 4 Down's syndrome (DS) patients with a 47,XY,21 + karyotype and from 4 normal male probands were cultured for 72 h in the presence of BrdU and lymphocytes analysed at their first mitosis for chromosomal aberrations. The frequencies of spontaneous aberrations and the proportions of cells in the first or later mitoses in culture were not different between the groups. Treatment with various doses of bleomycin in vitro resulted in similar delays in cell development for both DS and normal lymphocytes and dose-dependent increases in the incidence of chromosome-type aberrations. However, the induction of both dicentric aberrations and acentric fragments was significantly enhanced in DS cells relative to cells of normal karyotype.
D001761:Bleomycin / Q000494:pharmacology*; D001973:Bromodeoxyuridine / Q000494:pharmacology; D002869:Chromosome Aberrations; D002877:Chromosomes, Human / Q000187:drug effects; D004314:Down Syndrome / Q000235:genetics*; D006801:Humans; D007621:Karyotyping; D008214:Lymphocytes / Q000187:drug effects* / Q000502:physiology; D012016:Reference Values
D001761:Bleomycin; D001973:Bromodeoxyuridine